"The three-year data reinforce that Absorb may provide unique benefits not possible with metallic stents, including increases in the average area within the blood vessel, reduction in plaque and improved vessel movement over time," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands. "As the body of data and real-world experience increase for Absorb, we are seeing compelling evidence that a temporary scaffold that dissolves completely after doing its job represents the future of interventional cardiology treatment." 2
Also, at a recent PCR meeting in Rotterdam, data were presented from the ABSORB EXTEND study, a single-arm trial evaluating Absorb in patients with more complex heart disease than the ABSORB trial. Data from 450 patients enrolled in this trial showed that the rates of MACE at one year were slightly lower than a comparative set of data with a best-in-class drug eluting stent at the same follow-up period. In an analysis of 119 patients with diabetes from the ABSORB EXTEND trial, rates of MACE were comparable between patients with and without diabetes, a promising finding as event rates are typically higher in patients with diabetes when compared to patients without diabetes.
"Abbott's leadership in BVS research and development is unsurpassed, with a robust clinical program for Absorb targeting enrollment of nearly 14,000 patients around the world across a number of ongoing clinical studies. The long-term, three-year results from the ABSORB trial reinforce the strong clinical performance reported previously," said Charles A. Simonton, M.D., divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "Absorb represents the next revolution in interventional cardiology treatment, and Abbott is proud to be at the forefront of BVS clinical research to study Absorb in a wide range of patients with coronary artery disease."
About Coronary Artery DiseaseHeart disease is the leading cause of death for men and women around the world, and coronary artery disease (CAD) is the most common type of heart disease. 3,4 CAD is a condition in which the arteries that supply blood to the heart become narrowed or blocked by a buildup of plaque, which is composed of fat, cholesterol, calcium and other deposits that accumulate on the inner wall of the artery. Over time, the plaque hardens and narrows the coronary arteries, limiting the flow of oxygen-rich blood to the heart muscle. Areas of plaque can also rupture, causing a blood clot to form on the surface of the plaque. When blood flow to the heart is reduced or blocked, angina (chest pain) or a heart attack can occur. About the Absorb Bioresorbable Vascular Scaffold The Absorb Bioresorbable Vascular Scaffold, similar to a small mesh tube, is designed to open a blocked heart vessel and restore blood flow to the heart. Absorb is referred to as a scaffold to indicate that it is a temporary structure, unlike a metallic stent, which is a permanent implant.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV